Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM
Akira Mima, Yasuhiro Horii
{"title":"Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single-Centre Retrospective Study","authors":"Akira Mima,&nbsp;Yasuhiro Horii","doi":"10.1002/edm2.489","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight-loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Nine patients with CKD undergoing HD received weekly tirzepatide doses (2.5–7.5 mg) once a week. Evaluations encompassed tirzepatide's impact on dry weight (DW) and body composition assessed at baseline and study conclusion using bioelectrical impedance analysis. This longitudinal study included nine patients, with a median age of 53 years and median HD duration of 4 years.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Tirzepatide treatment significantly decreased glycated albumin compared with the value at baseline (22.7 ± 5.4 vs. 18.3 ± 2.5%, <i>p</i> = 0.028, respectively). Significant reductions were observed in DW (−1.0 kg, <i>p</i> = 0.024) and body mass index (−0.6 kg/m<sup>2</sup>, <i>p</i> = 0.050) following tirzepatide administration. Total fat mass was also reduced, but not significantly (− 2.51% from baseline, <i>p</i> = 0.214). In contrast, skeletal muscle mass was not decreased (−1.02% from baseline, <i>p</i> = 0.722). No serious side effects other than nausea were observed during the study period.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Tirzepatide effectively provides good glycaemic control in T2DM patients undergoing HD, decreasing DW by reducing body fat mass without increasing frailty risk.</p>\n </section>\n </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.489","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/edm2.489","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight-loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported.

Methods

Nine patients with CKD undergoing HD received weekly tirzepatide doses (2.5–7.5 mg) once a week. Evaluations encompassed tirzepatide's impact on dry weight (DW) and body composition assessed at baseline and study conclusion using bioelectrical impedance analysis. This longitudinal study included nine patients, with a median age of 53 years and median HD duration of 4 years.

Results

Tirzepatide treatment significantly decreased glycated albumin compared with the value at baseline (22.7 ± 5.4 vs. 18.3 ± 2.5%, p = 0.028, respectively). Significant reductions were observed in DW (−1.0 kg, p = 0.024) and body mass index (−0.6 kg/m2, p = 0.050) following tirzepatide administration. Total fat mass was also reduced, but not significantly (− 2.51% from baseline, p = 0.214). In contrast, skeletal muscle mass was not decreased (−1.02% from baseline, p = 0.722). No serious side effects other than nausea were observed during the study period.

Conclusion

Tirzepatide effectively provides good glycaemic control in T2DM patients undergoing HD, decreasing DW by reducing body fat mass without increasing frailty risk.

Abstract Image

替扎帕肽可减少接受血液透析的 2 型糖尿病患者的脂肪量并提供良好的血糖控制:单中心回顾性研究。
目的替扎帕肽是美国食品药品管理局批准用于治疗2型糖尿病(T2DM)的一种注射用多肽。其减肥效果主要针对减少脂肪,但对接受血液透析(HD)的慢性肾病(CKD)患者的减肥效果尚未见报道:九名接受血液透析治疗的慢性肾脏病患者每周接受一次替扎帕肽治疗(2.5-7.5 毫克)。评估包括在基线和研究结束时使用生物电阻抗分析评估替扎帕肽对干重(DW)和身体成分的影响。这项纵向研究包括 9 名患者,中位年龄为 53 岁,中位 HD 持续时间为 4 年:结果:与基线值相比,替扎帕肽治疗可显著降低糖化白蛋白(分别为 22.7 ± 5.4 vs. 18.3 ± 2.5%,p = 0.028)。服用替扎帕肽后,DW(-1.0 千克,p = 0.024)和体重指数(-0.6 千克/平方米,p = 0.050)显著下降。总脂肪量也有所减少,但并不显著(比基线减少 2.51%,p = 0.214)。相比之下,骨骼肌质量没有减少(与基线相比-1.02%,p = 0.722)。研究期间,除恶心外,未发现其他严重副作用:结论:替唑帕肽能有效控制接受 HD 治疗的 T2DM 患者的血糖,通过减少体脂量来降低 DW,同时不会增加虚弱风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and Metabolism Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
5.00
自引率
0.00%
发文量
66
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信